<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="754"><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>EBA of SQ-109 in Adult Subjects with Pulmonary TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71188"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="139433"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142516"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>420</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="210646"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A phase II pilot, placebo-controlled study to evaluate the efficacy of HE-2000 on opportunistic infections such as tuberculosis (TB) in late-stage AIDS patients</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9820"></Trial><Drug id="19980">HE-2000</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="52375"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>214</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10873"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10944"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="100728"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="100728"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="58503"></Trial><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase II, randomized, placebo-controlled study assessing the safety and efficacy of TMC-207 in patients with multidrug-resistant tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="57685"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>47</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="210646"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="102580"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3573</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="67014"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="61991"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87585"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I, controlled study to evaluate the pharmacokinetics and efficacy of PA-824 in patients with tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="70963"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>23</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87585"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10847"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10860"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>23</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10869"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="136263"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>98</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="78482"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142485"></Trial><Drug id="53724">artenimol + piperaquine (malaria), Sigma-Tau</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Safety of Moxifloxacin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76086"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="92275"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="145595"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201474"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="134374"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>243</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10650"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1004</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11181"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="195741"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A randomized, multiple-dose, open-label, phase II clinical study to evaluate the early bactericidal activity of rifalazil (PA-1648) and isoniazid (INH), as compared with INH alone or INH plus rifampin in patients with tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="20175"></Trial><Drug id="8658">rifalazil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="164024"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11181"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201302"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201474"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="153990"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>827</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="329497"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8751"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="250483"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="226815"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2516</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="132105"></Trial><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="226815"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2516</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="221844"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="363587"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220739"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224111"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224811"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Phase I Study of PBTZ-169</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="286724"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="253491"></Trial><Drug id="11089">nitazoxanide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC "Pharmasyntez", Russia) and Avelox tablets, film-coated, 400 mg ("Bayer Pharma AG", Germany)</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="247038"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8820"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="169098"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280225"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="293087"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>640</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="227340"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="219950"></Trial><Drug id="71323">Ad5Ag85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="37985"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="289837"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="242789"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Verapamil Dose-finding Study in Adult Patients with Tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="261260"></Trial><Drug id="44437">verapamil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214156"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9381"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="370128"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="303299"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280225"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase Ia, Placebo-controlled, Dose-Escalating study to test the Safety, Tolerability and Pharmacokinetics of Single dose of SQ-109 in 62 Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8945"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C1A">Phase 1a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>62</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360104"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360104"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244304"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effect of rosuvastatin on HIV TB coinfection</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="292154"></Trial><Drug id="12420">rosuvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228651"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8647"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369109"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="261481"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>31</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="338648"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="290705"></Trial><Drug id="70581">GSK-3036656</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A prospective, unblinded, non-randomized, single-center study to evaluate outcomes of bedaquiline-included regimens in multidrug-resistance/extensively drug-resistant (MDR/XDR) tuberculosis patients after 24 months and to identify factors predisposing the long-term treatment success</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="361163"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>167</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="298743"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9528"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>38</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase II trial to evaluate delamanid in pediatric patients with multi-drug resistance tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="341287"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="379769"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="375499"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="262931"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1802</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>THYB-04</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="285704"></Trial><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="235355"></Trial><Drug id="22216">etoricoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8801"></Trial><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>350</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201302"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I, single-ascending-dose study of OPC-167832 for the treatment of Mycobacterium tuberculosis infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="327014"></Trial><Drug id="104447">OPC-167832</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="337957"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="303756"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>74</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="183613"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>152</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="129005"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>160</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76946"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="265766"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76946"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201409"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201474"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87585"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10657"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="167750"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76946"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="82764"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A multicenter, randomized, 6-month study to compare the efficacy, tolerability and toxicity of two different regimens of rifabutin with that of rifampicin</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15869"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>520</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="56959"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71511"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71046"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>68</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="69926"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10871"></Trial><Drug id="5321">indinavir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10685"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>433</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="77668"></Trial><Drug id="71323">Ad5Ag85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="14589"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63729"></Trial><Drug id="6242">abacavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Rifapentine During Intensive Phase Tuberculosis (TB) Treatment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="17237"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>529</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="182646"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>7</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase IIb Clinical Study of new GSK Vaccine Candidate</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="137219"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="74529"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150793"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="215072"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10948"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="67996"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63801"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>182</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="82132"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>295</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A phase I, randomized, study to evaluate the efficacy of SRL-172 on cell-mediated immunity of patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="17288"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>101</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="222400"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="145651"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11177"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10948"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Clinical Challenge Study of BCG in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="177982"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="103573"></Trial><Drug id="49162">LL-3858</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A five year study to evaluate the safety and efficacy of SRL-172 in the prevention of tuberculosis in HIV-positive subjects</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="19967"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="169697"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>63</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="56959"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Moxifloxacin_QT Study in Chinese Healthy Volunteer</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="89715"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10947"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90512"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90788"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>114</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161096"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="182316"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10943"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="109063"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>365</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Trial of DAR-901</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="173446"></Trial><Drug id="90231">DAR-901</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="68204"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="207608"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>283</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="347635"></Trial><Drug id="12132">albendazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Tuberculosis Prevention for HIV Infected Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8790"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1148</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="303595"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Taima TB: 3-HP Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="254050"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="260814"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in China</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="370697"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220243"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228190"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="230529"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214156"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280225"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="352748"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224111"></Trial><Drug id="46931">cefadroxil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244777"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334027"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>RIFART</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131240"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="348056"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>488</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="321760"></Trial><Drug id="108779">GC-3107</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative study of different treatment regimes for brain tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="382387"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="25327"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="213394"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>183</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220739"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="368916"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="243619"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161441"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="347338"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244304"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I study to evaluate S-004992 in patients with tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="348025"></Trial><Drug id="61340">S-004992</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381490"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8644"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280651"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="247456"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8780"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="368916"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="6229">Infanrix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="368916"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9520"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360329"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="293734"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="374838"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>250</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="348056"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>488</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9320"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>14</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369109"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry>European Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="48943"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="50188"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="153990"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>827</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149562"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>101</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10648"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150793"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11181"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="168898"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="65639"></Trial><Drug id="12862">Tritanrix HB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="62096"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10855"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1836</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="86389"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A single-blind, randomized, safety study comparing rifabutin with rifampicin in the treatment of HIV-1-associated tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15878"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71107"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87507"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="69212"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="86312"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Phase II Trial of SCV-07 in TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="144312"></Trial><Drug id="25023">golotimod</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142231"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="138715"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10684"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>350</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="86312"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="136052"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10869"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10948"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="122291"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="83464"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase IIa, open-label, safety and immunogenicity study of MVA-85A in HIV- and/or Mycobacterium tuberculosis-infected adults</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="86807"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="113726"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Randomized, Double-blind, Multicenter, Placebo-controlled Trial to Study the Efficacy of Mycobacterium vaccae Immunotherapy for Tuberculosis in KwaZulu, South Africa, 1991-97</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="109626"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>204</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase III study to evaluate the safety and efficacy of aerosolized Actimmune for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in patients who have failed a treatment regimen of anti-tuberculosis therapy</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="14945"></Trial><Drug id="3365">Actimmune</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15754"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>481</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>RIFART</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131240"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Optimization of Tuberculosis and HIV Co-treatment in Africa</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131419"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>493</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10869"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Glutoxim in the Complex Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149460"></Trial><Drug id="28379">Glutoxim</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="235054"></Trial><Drug id="98373">TB/FLU-04L</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10947"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="60906"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150332"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162528"></Trial><Drug id="5369">ribavirin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>550</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10947"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150059"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142322"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="156675"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="169697"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>63</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="121916"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="79741"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11563"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59304"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A comparative, open-labeled, randomized study to evaluate the bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="114922"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>43</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="61991"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="243294"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3738</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase III trial of recombinant tuberculosis vaccine AEC/BC02 in patients with tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="352354"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="177457"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1002</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="167779"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142485"></Trial><Drug id="53041">artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="164292"></Trial><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="329251"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="246089"></Trial><Drug id="71742">TBA-354</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="222400"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="366672"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="300655"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="219499"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Metformin in tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="325158"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>316</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228190"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="384080"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety of RUTI Vaccination in MDR-TB Patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="256039"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>27</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="243619"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244304"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224111"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="384080"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="272021"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280651"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="377163"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>624</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="377163"></Trial><Drug id="25182">valganciclovir</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>624</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="329251"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="328802"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244304"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="365020"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369747"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="279727"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>102</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369747"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="379769"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334027"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="247763"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1090</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244777"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="260814"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="371202"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>108</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="374387"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>11</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="329251"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="182646"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>7</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of "NPP" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="194177"></Trial><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76946"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Phase Ic Study of Safety and PK of SQ-109 300 mg Daily</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="77682"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10681"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><TrialStatus>Suspended</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10863"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11177"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="65639"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I study to determine the safety of AERAS-402 in healthy adults, all of whom have been previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine and a subset of whom have evidence of having been exposed to tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59617"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="265899"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>64</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90175"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10945"></Trial><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59043"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="65639"></Trial><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Linezolid to Treat Extensively-Drug Resistant Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="23143"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>41</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161831"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>428</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="118547"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Multicenter, Prospective, Randomized, Controlled Trial to Assess  the Efficacy and Safety of Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis in China</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="183541"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="98566"></Trial><Drug id="44370">clindamycin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="92426"></Trial><Drug id="8050">thalidomide, Celgene</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="89833"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>248</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161275"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="40948"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="86312"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="91280"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="74529"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="15298">Pentacel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224781"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Interferon Alpha-2b in the Complex Therapy of Patients With Pulmonary Tuberculosis Concurrent With Broncho-obstructive Syndrome</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149989"></Trial><Drug id="45998">interferon alfa-2b</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10687"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10648"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131253"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11188"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150793"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10655"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10646"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study to evaluate the safety and efficacy of moxifloxacin in comparision with cephalexin in patients being treated for uncomplicated skin and soft tissue infections</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="16244"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>86</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="152200"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>217</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="133567"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A randomized, double-blinded, dose-ranging study to assess the 14-day early bactericidal activity of bedaquiline (TMC-207) in patients with sputum microscopy smear-positive pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="139369"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>68</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Bioavailability</Endpoint><ProtocolTitle>Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="177165"></Trial><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150793"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="120744"></Trial><Drug id="84564">ChAdOx1-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>42</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161275"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>A Bioavailability Study of Two New Formulations of Bedaquiline on Pediatric Populaion</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="163991"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I study to evaluate the safety and immunogenicity of a novel, proprietary prophylactic vaccine MTB72F to induce protection against tuberculosis (TB)</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9554"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10057"></Trial><Drug id="55173">cadi-05</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1020</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="201474"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="208141"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="242269"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="373676"></Trial><Drug id="107803">GamTBvac</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>180</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="333384"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="352729"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381674"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381674"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8820"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="255644"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>131</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220686"></Trial><Drug id="105321">superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>96</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I trial of S-004992 for the potential treatment of drug-resistant tuberculosis</ProtocolTitle><TrialStatus>Planned</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334482"></Trial><Drug id="61340">S-004992</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244777"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="257534"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="368916"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214156"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="328802"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334027"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="333435"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9315"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of GC-3107(BCG Vaccine) in Healthy Infants</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="380364"></Trial><Drug id="108779">GC-3107</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8776"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="347338"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="255234"></Trial><Drug id="85970">telacebec</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="297373"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="366261"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>12000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="226801"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="293734"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="319125"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase I, double-blind, randomized, placebo-controlled, safety and immunogenicity study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8499"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="341686"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1875</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="260814"></Trial><Drug id="72148">darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="340636"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>99</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="219931"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>192</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="362067"></Trial><Drug id="107010">TBI-223</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="17432"></Trial><Drug id="16755">pafuramidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>175</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="375499"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="276708"></Trial><Drug id="4718">zileuton</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="373668"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>320</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="343050"></Trial><Drug id="70581">GSK-3036656</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="372676"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="378146"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214156"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="279898"></Trial><Drug id="59386">CC-11050</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="263359"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="72716"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="187839"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1354</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Deworming Against Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="48176"></Trial><Drug id="12132">albendazole</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="139433"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150332"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="65984"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="23035"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>121</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="210646"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11188"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="67098"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="60906"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase I study to test the safety of AERAS-402 in healthy infants previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="53622"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="61991"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase II, dose escalation study to determine the safety of AERAS-402 in adults who have had active tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59557"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76756"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="295037"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63729"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of MVA-85A in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59405"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2797</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><TrialStatus>Suspended</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10863"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10657"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="19230"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="66735"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A multicenter, randomized controlled study to evaluate the clinical efficacy and safety of linezolid in patients with extensively drug resistant tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="173992"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90175"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="126486"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A phase I, double-blind, placebo-controlled, flexible single day ascending dose (SDAD) study to evaluate safety, tolerability and pharmacokinetics (PK) of iv AZD-5847 in healthy subjects</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="82840"></Trial><Drug id="26493">posizolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of LL-3858</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8931"></Trial><Drug id="49162">LL-3858</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63801"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>182</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>PK/PD of Ertapenem in Patients with TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="98848"></Trial><Drug id="12543">ertapenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161441"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="126486"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="120744"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>42</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="92275"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="12813">Rotarix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161275"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10646"></Trial><Drug id="8255">nelfinavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>RIFART</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131240"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="120522"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase III study to evaluate the safety and efficacy of SRL-172 for the prevention of tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="20002"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>347</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="48035"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="25327"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10946"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="83489"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>207</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10646"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="132087"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63261"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="100728"></Trial><Drug id="5321">indinavir</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10646"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A open-labeled study to assess the efficacy of levofloxacin in healthy volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="113606"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63729"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="160177"></Trial><Drug id="81037">Wei Ka</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214864"></Trial><Drug id="46927">doxycycline hyclate</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="195741"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Treatment of Latent Tuberculosis in Socially Marginalised Citizens</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="310930"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="285854"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="168261"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>92</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="291547"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="235751"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Study of Daily Rifapentine for Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="39550"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>153</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="227604"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>14</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="222933"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>262</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="242269"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Tuberculosis child multidrug-resistant preventive therapy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259562"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1556</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>A prospective, single-centre pharmacokinetic study to develop population pharmacokinetic models for second-line drugs in patients with multi-drug-resistant tuberculosis, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="304264"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="366580"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>107</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="254949"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC "Synthesis", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="255583"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="303756"></Trial><Drug id="107523">TBA-7371</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>74</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="368916"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="372353"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="210083"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="219499"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="222400"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="40948"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="168785"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9302"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>160</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280303"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="374083"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="372893"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase II Trial To Study SCV-07 in Tuberculosis (TB) Patients Receiving Standard Anti-TB Chemotherapy</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9345"></Trial><Drug id="25023">golotimod</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="246553"></Trial><Drug id="104087">FS-1</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>480</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="238674"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="379769"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280303"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="245694"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="301908"></Trial><Drug id="98373">TB/FLU-04L</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>80</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Phase I clinical trial of single-dose of PA-824</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="362102"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="375406"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8842"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369747"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228190"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360104"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB)</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="284370"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>380</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="292836"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381674"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="383209"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="252783"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="214864"></Trial><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="40948"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="285889"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>96</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="223463"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="303292"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280225"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="329251"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="374387"></Trial><Drug id="74480">doravirine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>11</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="65639"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="231367"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="47398"></Trial><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76765"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>33</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="23059"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Doxycycline in Human Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="261320"></Trial><Drug id="46927">doxycycline hyclate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10947"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10872"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10874"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioavailability</Endpoint><ProtocolTitle>A phase II trial of rifapentine in comparision with rifampicin to evaluate bioavailability in treatment of patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15342"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="56974"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>233</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TCell Turnover Following Vaccination With MVA-85A</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11182"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11188"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="126486"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of AERAS-402 in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="70158"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>487</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="210083"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="67841"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Treatment of Tuberculosis in HIV-Infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10643"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149504"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>53</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76765"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>33</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Phase I Trial to Compare Oral Formulation of Golotimod Versus that of Subcutaneous and Sublingual Formulations of Golotimod in Healthy Volunteers for the treatment of Tuberculosis (TB)</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8932"></Trial><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="80386"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>511</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="122291"></Trial><Drug id="3517">losartan</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="158535"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="145651"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="265899"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>64</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10948"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A dose-finding, multicenter, open-label study to investigate the efficacy of SRL-172 vaccine in the treatment of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="110339"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>337</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="114300"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="219499"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="162886"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71107"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10653"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>215</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150307"></Trial><Drug id="8050">thalidomide, Celgene</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="161275"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="171009"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Combination of Two Drugs in Tuberculosis Treatment</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224091"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="63729"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="227341"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="163196"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="113726"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of IL-2 for the treatment of patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="73321"></Trial><Drug id="6306">aldesleukin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="195741"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><TrialStatus>Suspended</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10863"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11263"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>181</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="229498"></Trial><Drug id="6748">Recombivax HB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>185</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="379095"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228560"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>566</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="114300"></Trial><Drug id="16696">lamivudine + zidovudine, GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="164313"></Trial><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="265766"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="354327"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="364544"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="316145"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>192</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="226826"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8820"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="44406">imipenem + cilastatin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study to evaluate the efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in patients with newly diagnosed pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280029"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="328802"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="227410"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>A study to evaluate the pharmacokinetics of levofloxacin in children who received levofloxacin-based tuberculosis preventive therapy</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="380303"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334027"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="331962"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="375499"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224675"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1044</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9540"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360104"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="347635"></Trial><Drug id="3412">ivermectin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Study of Linezolid for TB Meningitis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="340851"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="333435"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369109"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="256110"></Trial><Drug id="90231">DAR-901</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="330023"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>321</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10866"></Trial><Drug id="55173">cadi-05</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="199754"></Trial><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="68204"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="79741"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="155451"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>410</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="40948"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="100728"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10941"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="192117"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142323"></Trial><Drug id="12014">VP-101</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>288</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10681"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="150522"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10869"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Improving Retreatment Success</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="182040"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>58</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="93494"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>The Effect of Intermittent Rifampicin on Raltegravir</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="80394"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76756"></Trial><Drug id="62397">AERAS-407 rBCG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="122291"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90175"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Phase IIa EBA Trial of AZD-5847</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="84246"></Trial><Drug id="26493">posizolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="102102"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>108</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="49258"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1931</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10943"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87533"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="136052"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="83489"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>207</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="109063"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>365</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10681"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="91280"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="75317"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>817</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Challenge Model for Assessment of Human TB Immunity</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149358"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10656"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Glutoxim in the Surgical Treatment of Patients With Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="149224"></Trial><Drug id="28379">Glutoxim</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="136052"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10659"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>7731</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="42128"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="25800"></Trial><Drug id="39069">simeprevir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>21</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="176219"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>990</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="172626"></Trial><Drug id="3610">meloxicam</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="183939"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="127798"></Trial><Drug id="9354">picroliv</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>260</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A Non-randomized, Uncontrolled, Single-group Study of Short-course Isoniazid plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-organ Transplant Candidates</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="159244"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>17</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="359917"></Trial><Drug id="98013">isoniazid + rifampicin + pyrazinamide + ethambutol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="309614"></Trial><Drug id="107803">GamTBvac</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="331225"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Correlate of Risk Targeted Intervention Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="258043"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2927</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="281055"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4027</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in USA</ProtocolTitle><TrialStatus>Planned</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="370698"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="294801"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="228190"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="354327"></Trial><Drug id="84564">ChAdOx1-85A</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioequivalence</Endpoint><ProtocolTitle>Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="218651"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A comparative study to evaluate the use of 68Ga-tilmanocept in patients with tuberculosis (TB)</ProtocolTitle><TrialStatus>Planned</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="378644"></Trial><Drug id="116061">68Ga-tilmanocept</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="259506"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244304"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="247456"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="275657"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Statin Adjunctive Therapy for TB</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="331728"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="213394"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>183</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GX-70 in TB Patient</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="298965"></Trial><Drug id="53019">GX-70</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="221523"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="221844"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="279898"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="319125"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="271641"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="224811"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="247456"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="298711"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="286376"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="328802"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="372676"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="353987"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>125</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381674"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="293734"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="374838"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>250</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8791"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>146</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="319125"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Appropriate course of the treatment of tuberculous pleurisy</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="309137"></Trial><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>474</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An open-label, phase I trial to evaluate the safety, tolerability and immunogenicity of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8497"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="152200"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>217</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Tuberculosis Clinical Trials Consortium Study 35</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="359122"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="235355"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="42128"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="344335"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5610</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="361821"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381674"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>The safety and efficacy of high dose rifapentine in treatment of tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="359664"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>38</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="227111"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A multiple-ascending-dose and early-bactericidal-activity study to assess OPC-167832 in drug susceptible TB patients</ProtocolTitle><TrialStatus>Planned</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="327016"></Trial><Drug id="104447">OPC-167832</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase II Study of H56:IC31 in Healthy Adolescents</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="310653"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="353987"></Trial><Drug id="104447">OPC-167832</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>125</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="243619"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="298711"></Trial><Drug id="69974">cabotegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>RIFART</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131240"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="73200"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11188"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10681"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="199754"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="89135"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="208141"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="93494"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="80383"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>142</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131456"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10868"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>An open-label, active control trial of rifapentine to evaluate efficacy, in patients with pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15328"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>722</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="116439"></Trial><Drug id="44409">Fluzone</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>301</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A self-controlled, single-center Taiwanese study to assess the efficacy and tolerability of rifabutin for re-treating chronic cases of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="15897"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="114300"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="183613"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>152</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90314"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="71107"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="59134"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="76946"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="89135"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="61895"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="145651"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>RIFART</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="131240"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142540"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Latency in Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="67984"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="151743"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>66</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>PK and Bactericidal Activity in Sputum and Blood of PNU-100480 (Sutezolid, U-480) and its Major Metabolite (PNU-101603, U-603) in Patients with Pulmonary TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="128346"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Evaluate Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected with HIV and TB</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="147644"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A hospital-based retrospective study to assess the clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="234062"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="90512"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="230529"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10646"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10652"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>102</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11219"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10656"></Trial><Drug id="8255">nelfinavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10871"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11184"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Essentiality of INH in TB Therapy</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="87091"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><TrialStatus>Suspended</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="10863"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase II/III study to evaluate the safety and efficacy of SRL-172 for the treatment of tuberculosis</ProtocolTitle><TrialStatus>Suspended</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="19996"></Trial><Drug id="11115">IMM-201</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="89066"></Trial><Drug id="17132">pascolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="129536"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="114087"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="226826"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="23035"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>121</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="215600"></Trial><Drug id="71742">TBA-354</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02)</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="291253"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>175</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>The phase Ia clinical trial of pyrifazimine</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="356451"></Trial><Drug id="101474">small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica</Drug><DevStatus id="C1A">Phase 1a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>58</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="333435"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360329"></Trial><Drug id="46931">cefadroxil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="11187"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="230529"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="328144"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1A">Phase 1a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="244777"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Phase IIa Study of PBTZ-169</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="318771"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Optimizing Treatment to Improve TBM Outcomes in Children</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="278847"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase III study of delamanid in multidrug-resistant tuberculosis patients</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="323086"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="280651"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220739"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="269403"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2006</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="220243"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I trial to evaluate the safety, tolerability, pharmacokinetics of a single dose of PA-824</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="9416"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="300655"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="334027"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="343604"></Trial><Drug id="85970">telacebec</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I, singlecenter, open-label, prospective clinical study to assess safety, tolerability and pharmacokinetics of ascending doses of Q-203 in single use in healthy subjects</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="371518"></Trial><Drug id="85970">telacebec</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="307654"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="375813"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>566</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Single Ascending Dose Study Of BTZ-043</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="346718"></Trial><Drug id="70901">BTZ-043</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A double-blind, randomized, placebo-controlled, phase I study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8498"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="333435"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="223291"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>22</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="223463"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients></Row><Row><Ancestry>European Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="8888"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="23067"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="381962"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="298671"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>2000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="341686"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1875</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Synergistically acting Rifampicin and Faropenem in Tuberculosis</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="377088"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>56</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="379769"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="369109"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="360329"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="142322"></Trial><Drug id="66409">IMX-461</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="337163"></Trial><Drug id="4567">etanercept</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>174</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Efficacy, Safety and Pharmacokinetics of DTG With RIF</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Trial id="359086"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>